Aguirrezábal Arredondo A, Alvarez Lavín M, Yurrebaso Ibarreche M J, Vilella Ciriza M L, Elguézabal Ortúzar I, Goikolea Ugarte F J, Escobar Martínez A
Servicio de Farmacia. Hospital de Basurto. Bilbao. Spain.
Farm Hosp. 2003 Jul-Aug;27(4):219-23.
To analyse errors detected in the prescription of cytostatic drugs.
Prospective study (February 1st to April 15th, 2002). All medical orders containing cytostatic agents were checked and 13 variables were studied: identification, anthropometric data, diagnosis, protocol, number of cycles, cytostatic drug, length of treatment, dose, route of administration, volume of infusion and/or final concentration, infusion time, diluent, and doctor's signature. Several possible errors were identified for each variable. Information on whether it was the first cycle, prescribing service, and prescription format was also recorded.
In all, 618 medical orders were reviewed for a total of 1178 lines of cytostatic agents and 2,171 doses. The possible number of errors was 12.101 and the total number of errors actually found was 2,706 (22,03%). Not all these errors had the same impact on patients. Errors by omission were 2,340 (87,77%). Those which nursing staff found difficult to check and/or administer stood at 281 (10,54%). Potentially serious errors numbered 60 (2.06%): wrong body area > 10%: 5; wrong body area 5-10%: 2; erroneus protocol: 2; incorrect volume: 16; wrong dosage: 23 (difference < 25%: 5; difference 10-25%: 14; difference < 10%: 4). Reductions indicated but not implemented: 9; Inappropiate diluent: 3. There were no incorrect or omitted medications.
The description of such errors and their uantification is a useful method of quality asurance in order to establish appropiate corrective measures. The most common error was the omission of information and therefore this issue, along with the development of computerised prescriptions, should be addressed.
分析细胞毒性药物处方中发现的错误。
前瞻性研究(2002年2月1日至4月15日)。检查所有含有细胞毒性药物的医嘱,并研究13个变量:识别信息、人体测量数据、诊断、治疗方案、疗程数、细胞毒性药物、治疗时长、剂量、给药途径、输注量和/或最终浓度、输注时间、稀释剂以及医生签名。针对每个变量识别出了几种可能的错误。还记录了关于是否为首个疗程、开方科室和处方格式的信息。
共审查了618份医嘱,涉及1178行细胞毒性药物和2171剂药物。可能出现的错误数量为12101个,实际发现的错误总数为2706个(22.03%)。并非所有这些错误对患者的影响都相同。漏记错误有2340个(87.77%)。护理人员难以检查和/或执行的错误有281个(10.54%)。潜在严重错误有60个(2.06%):体表面积错误>10%:5个;体表面积错误5 - 10%:2个;治疗方案错误:2个;容量错误:16个;剂量错误:23个(差异<25%:5个;差异10 - 25%:14个;差异<10%:4个)。标明但未实施的减量:9个;不适当的稀释剂:3个。没有药物开错或漏开的情况。
描述此类错误及其量化是一种有用的质量保证方法,以便制定适当的纠正措施。最常见的错误是信息遗漏,因此这个问题以及计算机化处方的开发都应得到解决。